Skip to main content

Features of chinese patients with sitosterolemia

Abstract

Background

Sitosterolemia is a lipid disorder characterized by the accumulation of phytosterols in plasma and organs, caused by mutations in the ABCG5 and/or ABCG8 genes. The disease is frequently misdiagnosed and mistreated as familial hypercholesterolemia (FH). To gain a better understanding of the disease, the current status of diagnosis and treatment of Chinese patients with sitosterolemia was reviewed and summarized.

Method

Literature search was performed. The clinical features and molecular characteristics of Chinese patients with sitosterolemia were analysed. Four children with sitosterolemia and the treatment experience were described.

Results

Fifty-five patients with sitosterolemia have been reported in China. These patients were aged from 3 months to 67 years at diagnosis, and the median was 8 years of age. Several complications, such as xanthomas in 47 patients (85%), thrombocytopenia in 17 patients (31%), anemia in 14 patients (25%), and cardiovascular damage in 12 patients (22%), were observed. Thirty-nine patients (71%) exhibited mutations in the ABCG5 gene, 15 patients (27%) showed mutations in ABCG8, and variations in both genes occurred in one patient (2%). A patient with two clinically rare diseases, namely, sitosterolemia and glycogen storage disease type VI (GSD VI)), is reported here for the first time. The four reported patients were treated with low cholesterol and phytosterol-limited diet alone or combined with cholestyramine. Even though decreases were observed for total plasma cholesterol (TC) and low-density-lipoprotein cholesterol (LDL-C), and these levels were as low as normal in some patients, the levels of plant sterols remained above the normal range. However, TC, LDL-C and plant sterol levels remained at high levels in patients treated with a control diet control only.

Conclusions

The analysis reveals that different from Caucasians carrying mainly variations in ABCG8, most Chinese patients have mutations in the ABCG5 gene, and Arg446Ter, Gln251Ter, anArg389His might be hot-spot mutations in Chinese patients. The current survey provides clinical data to enable the development of a standardized protocol for the diagnosis and treatment of sitosterolemia in China.

Background

Sitosterolemia (MIM# 210,250) is a rare autosomal recessive hereditary metabolic disease and a lipid metabolism disorder characterized by increased absorption and decreased excretion of dietary phytosterols, primarily due to mutations in the ABCG5 and/or ABCG8 genes [1,2,3]. Sitosterolemia usually results in significantly increased plasma levels of phytosterols, namely sitosterol, cholestanol, campesterol and stigmasterol. Patients with sitosterolemia suffer from xanthomas, hypercholesterolemia, accelerated atherosclerosis, and liver dysfunction. Hematological abnormalities, including macrothrombocytopenia, hemolysis, anemia and stomatocytosis, have been reported [4, 5]. Sitosterolemia is highly heterogeneous clinically, varying widely from asymptomatic to premature cardiac death [6]. It is often misdiagnosed as familial hypercholesterolemia in the early stage, resulting in inappropriate dietary intervention consisting of plant-based foods high in phytosterol, leading to serious vascular complications [7]. Ezetimibe, a selective cholesterol absorption inhibitor, is currently used as a first-line agent to treat sitosterolemia patients in Western countries [8,9,10]. Although ezetimibe and cholestyramine have been widely used in the treatment of sitosterolemia, the unified consensus on the drug dosage and the intake of plant sterols during dietary therapy have not been reached, especially for infantile patients [11]. In China, the diagnosis and treatment of pediatric patients with sitosterolemia remain a challenge for clinicians. To expand the knowledge and reported information regarding clinical experiences related to sitosterolemia, the natural history and follow-up assays for four sitosterolemia children were traced and reported here. Literature review on clinical presentation and molecular characteristics of a total of 55 Chinese patients was conducted by collecting information from accessible databases, as well as internet sources, such as PubMed, Wiper database, Baidu Scholar, China National Knowledge Infrastructure (CNKI), and Wanfang Data [12,13,14,15,16,17,18,19,20,21].

Glycogen storage disease type VI (GSD VI) (MIM #232,700) is an autosomal recessive disease confirmed to be caused by mutations in the gene that encodes glycogen phosphorylase (PYGL), resulting in significantly elevated glycogen accumulations in the liver. The PYGL gene, located on chromosome 14 (14q22.1), consists of 20 exons. According to the Human Gene Mutation Database, 69 mutations have been reported in the PYGL gene. The clinical manifestations of this disease include hepatomegaly, growth retardation, mild hypoglycemia, hypertriglyceridemia, increased liver transaminases and ketosis in the early childhood stage. Muscular hypotonia and lactic acid elevation after meals have also been reported in some cases [22, 23]. Small frequent meals are recommended in all patients with GSD VI. Uncooked cornstarch has been proven to be effective in maintaining blood sugar stability and preventing ketosis, so patients are also recommended to eat uncooked cornstarch before bed [24].

Case presentation

The four patients were from four separate healthy nonconsanguineous Chinese parents. All the patients had a normal birth history, except for case 4, who was conceived by in vitro fertilization (IVF). None had a family history of hypercholesterolemia, xanthoma, or early onset of cardiovascular diseases. Table 1 shows the clinical characteristics. All had normal complete blood cell counts and normal blood cell morphology on blood smears. Color Doppler ultrasonic studies revealed normal bilateral carotid artery blood flows in all patients. No abnormality was observed on electrocardiogram and echocardiography. The diagnosis of sitosterolemia was delayed in all four patients, up to six years and eight years, in patients 1 and 3 respectively.

Table 1 Baseline lipid profiles, liver enzymes, and blood cell counts of 4 Chinese children with sitosterolemia

Case 1, a 12-year-old girl, presented with multiple xanthomas at her buttocks, wrists and ankles since she was three years old. The girl also exhibited a dramatically high level of total plasma cholesterol (TC) (624 mg/dL) and normal level of triglycerides (TGs). She underwent surgical excision of the xanthomas when she was 5 years old, and the histopathology examination confirmed xanthomas. She was initially misdiagnosed as FH and was treated with atorvastatin (5 mg/d) and diet modification (diet low in fat and cholesterol, high in fiber). The TC and low-density-lipoprotein cholesterol (LDL-C) levels remained elevated, and the xanthomas continued to increase in size and number.

Hence, she was referred for further evaluation at 9 years old. Height and weight were approximately in the last 25th percentile, and the body mass index was 14.9 kg/m2. Blood tests revealed normal levels of liver enzymes, blood glucose, coagulation parameters, and creatinine. Abdominal ultrasound showed no hepatosplenomegaly or fatty liver. Levels of serum plant sterols, such as β-sitosterol (506 µmol/L) and campesterol (110 µmol/L) were dramatically increased. Genetic analysis showed hybrid ABCG5 gene mutant p.Met302Asn fs*82 (c.904+1G>A) and p.His510Asn (c.1568 C>A).

Treatment was changed to cholestyramine (1 g four times daily) combined with diet control (low in cholesterol and phytosterols). Xanthomas increased in the first 4 months, then decreased gradually, and finally almost disappeared after 1 year of treatment. The TC and LDL-C levels normalized after 1 year of treatment. Despite a 2-year cholestyramine treatment, her plasma plant sterol level remained high (Table 1).

Patient 2, showed elevated liver enzymes and enlarged liver size since 3 years old. When she was admitted to our center at 4 years and 8months old, her body height and weight (97.2 cm and 15.3 kg) were between the 3rd and 10th percentiles. The body mass index 16.2 kg/m2 was normal. Blood tests showed mild normochromic anemia with normal platelet count, markedly elevated levels of ALT and AST; moderate increase in lactic acid [1.81 mmol/L, normal range (NR) < 1.7 mmol/L] and β-hydroxybutyrate (2.69 mmol/L, NR: 0.02-1.8 mmol/L) levels. Blood glucose, coagulation parameters, and creatinine were normal. Serum lipid profiles showed increased LDL-C level (146 mg/dL), whereas the TG (194 mg/dL) and TC levels were normal. Serum albumin level (36.9 g/L) was mildly reduced (NR: 40-55 g/L). Color Doppler ultrasonography revealed hepatosplenomegaly with an oblique diameter of 97 mm in the right liver lobe. Liver biopsy demonstrated extensive water degeneration in the liver cells; however, no significant inflammatory cell infiltration or fibrosis was observed.

Genetic analysis by whole-exome sequencing (WES) detected compound heterozygous mutations in both the PYGL and ABCG5 genes. Measurement of serum sterols by gas chromatography detected elevated β-sitosterol and campesterol levels (Table 1).

After the diagnosis was revised to GSD VI and sitosterolemia, oral cornstarch (1 g/kg per-dose, twice a day) was started, and the intake of cholesterol and plant sterols (<250 mg/day) was restricted. After two and a half years of treatment, the liver size, liver transaminase and TG levels normalized, and no signs of liver fibrosis were observed. However, there was no improvement in the blood sitosterol levels (Table 1). Cutaneous xanthomas were not observed within the entire treatment course.

Patient 3 had increased cholesterol levels since 7 years of age. On physical examination, both height and weight were on the 3rd percentile, and the body mass index (13.7 kg/m2) was normal. Xanthoma was not found on the skin. Hypercholesterolemia was detected. Quantitative analysis of serum sterol levels showed very high β-sitosterol and campesterol concentrations (Table 1), indicating the occurrence of sitosterolemia. She was treated with cholestyramine, combined with a low-phytosterol diet. The serum cholesterol concentration normalized after four months of treatment. However, her serum sitosterol level remained high despite treatment for 2 years and 9 months (Table 1).

Patient 4, a 2-year-old boy, had cutaneous xanthomas on both ankles noted since 1 year and 5 months old. The preliminary laboratory examination indicated markedly elevated TC, LDL-C, and TG levels of 911 mg/dL, 762 mg/dL and 92 mg/dL, respectively. He was treated with dietary modification limiting milk (breast & formula) intake to 300-400 mL per day. Solid foods, mainly rice, meats, vegetables and one egg per day, were administered.

Upon referral to the tertiary center, his height and weight were in between the 10th and 25th percentiles, and the body mass index 15.2 kg/m2 was normal. He had multiple xanthomas at the elbows, ankles and gluteal folds. After the diagnosis of sitosterolemia was made based on elevated serum plant sterol levels, he received a low-cholesterol and low-phytosterol diet (avoiding vegetable oils, nuts, egg yolks and cereals, reducing milk to 150 mL per day, and excluding formula milk). Unfortunately, his serum cholesterol and sitosterol concentrations remained high after 8 months of dietary intervention (Table 1).

Methods

The serum sitosterol levels were determined by a gas chromatography-mass spectrometric analyzer (GCMSQP2010 Plus, SHIMADZU, Japan), as described by Bratinčević MV et al. [25].

Genomic DNA (gDNA) was extracted from the peripheral blood of the patients as well as their parents using a DNeasy Blood & Tissue Kit ((Qiagen, Hilden, Germany). All the probands’ DNA samples were first amplified by PCR using specific primers for the ABCG5 and ABCG8 genes. The primers used for gDNA amplification and sequencing of ABCG5 and ABCG8 were designed by strictly following the descriptions in a previous article [26]. For WES (performed for patient 2) the manufacturer’s protocol was strictly followed for the entire workflow. The SureSelect Human All Exon V6 Kit (Agilent, California, USA) was used for library construction and capture experiments. DNA fragments were sequenced on the Illumina HiSeq 2500 platform. The captured variants were annotated by retrieval from SNP databases and the Human Gene Mutation Database (HGMD) (www.hgmd.cf.ac.uk). For novel variants absent from the HGMD, other existing databases, such as PROVEAN, SIFT, Mutation Taster, PolyPhen-2, Mutation Accessor and FATHMM, were used to predict pathogenicity.

Informed consent was obtained from all patients’ parents. The study was approved by the ethics committee of Guangzhou Women and Children’s Medical Center.

Results of mutation analysis

No mutations were found in the ABCG8 gene. In the ABCG5 gene, six mutations were identified, including 1 splicing mutation, 3 missense mutations and 2 nonsense mutations (Table 1). Among them, the splicing mutation c.904+1G>A (p.Met302Asn fs*82) located at exon 8 has been reported previously [27]. The mutation c.1568 C>A (p.His510Asn) located at exon 11 resulted in the replacement of histidine (His) by asparagine (Asn) at position 510. The mutation p.Ser44Pro (c.130T>C) located at exon 1 led to a change in serine (Ser) to proline (Pro) at position 44. The mutation p.Arg389His (c.1166G>A) located at exon 9 caused the replacement of arginine (Arg) with histidine (His) at position 389. Two nonsense mutations, c.64 C>T (p.Glu22Ter) and c.751 C>T (p.Gln251Ter), located at exon 1 and exon 6, respectively, initiated a stop codon of glutamine (Gln) at positions 22 and 251.

In addition to mutations in the ABCG5 gene, we also found hybrid heterozygous mutations in the PYGL gene in patient 2. The mutation c.1149 A>C (p.Glu383Asp) located at exon 10 caused the replacement of the glutamic acid (Glu) residue at position 383 with aspartic acid (Asp). Another mutation was a gross deletion mutation of PYGL exons 14–17.

Review of the Chinese patients

The relevant literature was searched in PubMed and Chinese databases, such as CNKI and Wanfang Data. According to the literature search, from year 2002 to 2020, 55 patients with sitosterolemia, have been reported in Taiwan and mainland China. These patients included 29 females and 26 males aged 3 months to 67 years, and the median age at diagnosis was 8 years. The ABCG5 and/or ABCG8 genes were analyzed for these 55 patients to confirm the diagnosis of sitosterolemia, serum sitosterol assays were performed for 40 of the 55 patients.

Among these patients, the minimum age for symptom onset was 3 months (cases 3 and 4, a pair of siblings), and the maximum age at diagnosis was 67 years (patient 20). Xanthomas occurred in 47 patients (85%), thrombocytopenia in 17 patients (31%), anemia in 14 patients (25%), and cardiovascular damage (Table 2) in 12 patients (22%) (Fig. 1).

Table 2  A summary of clinical findings, laboratory serum lipid profiles, and ABCG5/ABCG8 mutations in 55 Chinese sitosterolemia patients
Fig. 1
figure 1

The proportion of clinical manifestations in 55 Chinese patients with sitosterolemia

Among all the reported patients, 39 (71%) had ABCG5 mutations, and 15 (27%) had ABCG8 mutations. Only one patient (2%) had both ABCG5 and ABCG8 mutations. Some mutations have been reported previously, while several mutations were identified for the first time. Among these mutations, Arg446Ter, Gln251Ter, and Arg389His at ABCG5 were present in 18 out of 27 patients (67%) with sitosterolemia (Table 2).

Discussion

With complicated and varied clinical manifestations, it is difficult to diagnose sitoterolemia and treat in the early stage. Persistent high cholesterol levels can cause premature coronary artery disease; therefore, early diagnosis and treatment are very important for patients with sitosterolemia. For Chinese patients, the minimum age at which carotid artery plaques developed was 2 years old (patient 43). The correlation between blood levels of plant sterols and premature coronary artery disease is not clear. In patients with lipid disorders, lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease [28]. High Lp(a) levels have been related to worse cardiovascular prognosis [29], However, Lp(a) was normal in the four patients described here and other reported patients [21].

Routine biochemical testing cannot distinguish phytosterols from cholesterol. The quantitative measurement of blood phytosterol concentrations, which requires special equipment and technology, is still the gold standard for the diagnosis of sitosterolemia. However, most local clinical laboratories may not have this equipment. In this study, the natural history and follow-up of four pediatric patients with sitosterolemia were described; and the clinical manifestations and gene mutations of 55 Chinese patients with sitosterolemia were analysed and summarized. One case (patient 2) of sitosterolemia combined with GSD VI was reported for the first time. The ABCG5 and/or ABCG8 genes were analyzed in all 55 patients in the previously studied Chinese cohort. There was no significant difference in the clinical symptoms between the Chinese and Caucasian patients. In contrast to mainly variations in ABCG8 gene in Caucasians, most Chinese patients have mutations in ABCG5 [30, 31], and Arg446Ter, Gln251Ter, and Arg389His might be hot-spot mutations in Chinese patients.

The majority of patients with sitosterolemia had delayed diagnosis, the delay from onset to diagnosis had been reported to be up to 28.8 years [14, 15]. In the present cohort, the mean age of symptom onset was 2.2 years, and the mean age of diagnosis was 6.4 years. Misdiagnosis often led to inappropriate treatment. Twenty Chinese patients with splenomegaly underwent a splenectomy at the ages of 9 to 61 years old [15]. The symptoms of anemia were greatly improved after splenectomy in patients with sitosterolemia, but platelet counts remained persistently low. Some patients with thrombocytopenia were administered steroids [14, 30]. Both patient 1 and patient 3 were misdiagnosed with FH and were treated with statins, resulting in worsening of the symptoms after 1 to 2 years of therapy.

Hybrid heterozygous mutations were identified in both the PYGL and ABCG5 genes by WES in patient 2, and Sanger sequencing verification was performed. The missense mutation p.Glu383Asp of PYGL, occurring in a highly conserved residue, was a novel mutation and was predicted to be damaging using the SIFT algorithm, Polyphen-2, and Mutation-Assessor for protein functions. Replacement of the amino acids might affect the stability of the protein structure, which might disrupt the positioning and binding of protein substrates and their catalytic sites. The other detected PYGL mutation, gross deletion of PYGL exons 14–17, was previously reported in a Chinese patient [32], PYGL exons 14 to 17 encode approximately one-fifth of the length of the protein.

Xanthomas were observed in only 2 out of the 4 patients (patient 1 and patient 4). Only patient 2 had hepatomegaly, significant liver enzyme elevation, high TGs, mild elevation of lactic acid and ketosis which are consistent with the diagnosis of GSD VI, in addition to high TC. She was treated with uncooked cornstarch and responded very well to the treatment as her liver size, liver transaminases, triglycerides and lactic acid were all normalized and remained normal on follow-up at 3 years after treatment was started. No hypoglycemia was detected during the entire course of the disease. Partial catch-up growth was observed with her height and weight crossing up centile lines from 3rd to 10th percentiles before treatment to the 25th percentile 3 years after the treatment was started. However, the plant sterols remained elevated. The catch-up growth she demonstrated with the treatment suggested that GSD VI, rather than sitosterolemia, was the main factor affecting her growth and development.

Regarding the drug treatment of sitosterolemia, some Chinese patients were treated with ezetimibe at a dose of 5 mg/d or 10 mg/d. The majority showed good response to this therapy. However, the infant who received ezetimibe at an early age of 3 months did not respond to the treatment. Another very young patient who was started on ezetimibe treatment at the age of 2 years showed a slower response than the adult patients with sitosterolemia [13,14,15, 33].

In this cohort, patients 1 and 3 received dietary restriction combined with cholestyramine, while patients 2 and 4 underwent dietary treatment alone. Eight months to 3 years of follow-up of the patients revealed that TC levels remained in the normal range and xanthomas disappeared gradually after combined dietary and cholestyramine treatment. Nevertheless, the levels of plant sterols remained high. Dietary treatment alone failed in the two patients, especially for the younger patient 4 (Table 1). Different plant sterol intakes due to different diets might be the main cause of the unsatisfactory effect of treatment in infantile patients. However, it cannot be concluded whether the poor response to dietary treatment in patient 2 is related to GSD VI. Uncooked cornstarch contains a high amount of plant sterol, up to 60 mg/100 g [34], while sitosterolemia requires a low-phytosterol diet. Hence, it is a great challenge to balance them.

In conclusion, although pharmacotherapy including ezetimibe and cholestyramine has been established as the standard of care, there is still no consensus on sitosterolemia treatment, especially for children under 2 years old. Treatment should be started immediately at diagnosis. Limiting phytosterols and cholesterol should be the first strategy (Fig. 2) [35, 36]. For patients with an incomplete response to ezetimibe, combination with cholestyramine may be a feasible additional treatment [11]. The treatment experience in this cohort suggested that a significant effect cannot be achieved with a small dose of cholestyramine. However, more studies are required to examine whether to combine the drugs or to increase the dose. Based on the current therapeutic outcomes, after obtaining parental consent, ezetimibe was started in the four patients. An ongoing study is expected to provide further information.

Fig. 2
figure 2

The sitosterolemia diagnosis and treatment flowchart

Misdiagnosis still frequently occurs for sitosterolemia in China, and many patients undergo unnecessary operations due to misdiagnosis. However, there is no unified diagnostic criteria for sitosterolemia. Measurement of plasma plant sterols should be considered in patients with considerably elevated cholesterol levels and negative genetic tests for FH, especially when there is concomitant xanthomatosis.

Comparisons with other studies and what does the current work add to the existing knowledge

Most previous studies [12, 14,15,16,17,18, 21] were case reports, and most of the Chinese patients did not have data on treatment and follow-up. Currently, there is no study summarizing the clinical characteristics and gene mutation types of Chinese sitosterolemia patients. In this study, an in-depth summary of the phenotype and genotype of sitosterolemia patients in China is provided. Notably, four pediatric sitosterolemia cases are described, and in particular, one case featuring a concomitant GSD VI mutation is reported for the first time.

Study strengths and limitations

Currently, sitosterolemia pediatric cases in China have rarely been reported. The strength of the current study is that it comprehensively collected related information for sitosterolemia patients among Chinese patients and summarized the data in depth to provide meaningful guidance for the treatment of such diseases in the clinic. The limitations of this study are small sample size and the short follow-up visit periods, in particularly for patients 2 and 4. To address the shortcomings, further follow-up visits and systematic monitoring for all four pediatric patients will be conducted.

Conclusions

This study reported four patients with sitosterolemia and reviewed a total of 55 Chinese patients. Morbidity can occur early in life for most patients. Therefore, it is essential to conduct plasma phytosterol assays for patients featuring early onset xanthomas and hypercholesterolemia with poor response to statins. Special attention should be given to patients with previous morbidity of coronary artery disease as well as patients presenting with hematological symptoms of macrothrombocytopenia and stomatocytic hemolysis. Early diagnosis and treatment can prevent complications and improve the prognosis for patients.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Patel SB, Salen G, Hidaka H, Kwiterovich PO, Stalenhoef AF, et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest. 1998;102(5):1041–4.

    CAS  Article  Google Scholar 

  2. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771–5.

    CAS  Article  Google Scholar 

  3. Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet. 2001;27(1):79–83.

    CAS  Article  Google Scholar 

  4. Rees DC, Iolascon A, Carella M, O’marcaigh AS, Kendra JR, et al. Stomatocytic hemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the hematological presentation of phytosterolaemia. Br J Haematol. 2005;130(2):297–309.

    CAS  Article  Google Scholar 

  5. Wang Z, Cao L, Su Y, et al. Specific macrothrombocytopenia/hemolytic anemia associated with sitosterolemia. Am J Hematol. 2014;89(3):320–4.

    CAS  Article  Google Scholar 

  6. Yoo EG. Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. Ann Pediatr Endocrinol Metab. 2016;21(1):7–14. Epub 2016/04/23.

    Article  Google Scholar 

  7. Escolà-Gil JC, Quesada H, Julve J, Martín-Campos JM, Cedó L, Blanco-Vaca F. Sitosterolemia: diagnosis, investigation, and management. Curr Atheroscler Rep. 2014;16(7):424.

    Article  Google Scholar 

  8. Othman RA, Myrie SB, Jones PJ. Non-cholesterol sterols and cholesterol metabolism in sitosterolemia. Atherosclerosis. 2013;231(2):291–9.

    CAS  Article  Google Scholar 

  9. Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, Masuda D, Ohama T, Yamashita S. Current therapy for patients with sitosterolemia – effect of ezetimibe on plant sterol metabolism. J Atheroscler Thromb. 2010;17(9):891–900.

    CAS  Article  Google Scholar 

  10. Sudhop T, Lütjohann D, von Bergmann K. Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol Ther. 2005;105(3):333–41.

    CAS  Article  Google Scholar 

  11. Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology. 2006;130(6):1853–7.

    Article  Google Scholar 

  12. Lam CW, Cheng AW, Tong SF, Chan YW. Novel donor splice site mutation of ABCG5 gene in sitosterolemia. Mol Genet Metab. 2002;75(2):178–80.

    CAS  Article  Google Scholar 

  13. Niu DM, Chong KW, Hsu JH, Wu TJ, Yu HC, Huang CH, Lo MY, Kwok CF, Kratz LE, Ho LT. Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children. J Inherit Metab Dis. 2010;33(4):437–43.

    CAS  Article  Google Scholar 

  14. Wang Z, Cao L, Su Y, Wang G, Wang R, Yu Z, Bai X, Ruan C. Specific macrothrombocytopenia/hemolytic anemia associated with sitosterolemia. Am J Hematol. 2014;89(3):320–4.

    CAS  Article  Google Scholar 

  15. Cao LJ, Yu ZJ, Jiang M, Bai X, Su J, Dai L, Ruan CG, Wang ZY. Clinical features of 20 patients with phytosterolemia causing hematologic abnormalities. Zhonghua Yi Xue Za Zhi. 2019;99(16):1226–31 Chinese.

    CAS  PubMed  Google Scholar 

  16. Hu M, Yuen YP, Kwok JS, Griffith JF, Tomlinson B. Potential effects of NPC1L1 polymorphisms in protecting against clinical disease in a chinese family with sitosterolaemia. J Atheroscler Thromb. 2014;21(9):989–95.

    CAS  Article  Google Scholar 

  17. Wang Y, Guo YL, Dong QT, Li JJ. Severe aortic valve stenosis in a 14-year-old boy with sitosterolemia. J Clin Lipidol. 2019;13(1):49–53.

    Article  Google Scholar 

  18. Fang D, Liang LL, Qiu WJ, Fan YJ, Sun Y, Yan H, Yu YG, Gu XF. Clinical, molecular genetic analysis, and treatment of 3 children with sitosterolemia. Zhonghua Er Ke Za Zhi. 2018;56(6):435–9 Chinese.

    CAS  PubMed  Google Scholar 

  19. Huang D, Zhou Q, Chao YQ, Zou CC. Clinical features and genetic analysis of childhood sitosterolemia: Two case reports and literature review. Medicine. 2019;98(15):e15013.

    Article  Google Scholar 

  20. Xu L, Wen W, Yang Y, Xie J, Li R, Wu Y, Hu Y, Wang L, Chong M. Features of Sitosterolemia in Children. Am J Cardiol. 2020;125(9):1312–6.

    Article  Google Scholar 

  21. Sun W, Zhang T, Zhang X, Wang J, Chen Y, Long Y, et al. Compound heterozygous mutations in ABCG5 or ABCG8 causing Chinese familial Sitosterolemia. J Gene Med. 2020;22(8):e3185.

    CAS  Article  Google Scholar 

  22. Beauchamp NJ, Taybert J, Champion MP, Layet V, Heinz-Erian P, et al. High frequency of missense mutations in glycogen storage disease type VI. J Inherit Metab Dis. 2007;30(5):722–34.

    CAS  Article  Google Scholar 

  23. Kishnani PS, Goldstein J, Austin SL, Arn P, Bachrach B, et al. ACMG Work Group on Diagnosis and Management of Glycogen Storage Diseases Type VI and IX. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21(4):772–89.

    Article  Google Scholar 

  24. Nakai A, Shigematsu Y, Takano T, Kikawa Y, Sudo M. Uncooked cornstarch treatment for hepatic phosphorylase kinase deficiency. Eur J Pediatr. 1994;153(8):581–3.

    CAS  Article  Google Scholar 

  25. Bratinčević MV, Visković T, Sutlović D. Comparison of the solid phase and liquid-liquid extraction methods for methadone determination in human serum and whole blood samples using gas chromatography/mass spectrometry. Arh Hig Rada Toksikol. 2017;68(4):308–14.

    Article  Google Scholar 

  26. Hubacek JA, Berge KE, Cohen JC, Hobbs HH. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum Mutat. 2001;18:359–60.

    CAS  Article  Google Scholar 

  27. Escolà-Gil JC, Quesada H, Julve J, Martín-Campos JM, Cedó L, Blanco-Vaca F. Sitosterolemia: diagnosis, investigation, and management. Curr Atheroscler Rep. 2014;16(7):424.

    Article  Google Scholar 

  28. Cesaro A, Schiavo A, Moscarella E, Coletta S, Conte M, Gragnano F, et al. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. J Cardiovasc Med (Hagerstown). 2021;22(3):151–61.

    CAS  Article  Google Scholar 

  29. Gragnano F, Fimiani F, Di Maio M, Cesaro A, Limongelli G, Cattano D, Calabrò P. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med. 2019;14(4):621–5.

    Article  Google Scholar 

  30. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771–5.

    CAS  Article  Google Scholar 

  31. Niu DM, Chong KW, Hsu JH, Wu TJ, Yu HC, et al. Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children. J Inherit Metab Dis. 2010;33(4):437–43.

    CAS  Article  Google Scholar 

  32. Luo X, Hu J, Gao X, Fan Y, Sun Y, Gu X, Qiu W. Novel PYGL mutations in Chinese children leading to glycogen storage disease type VI: two case reports. BMC Med Genet. 2020;21(1):74.

    CAS  Article  Google Scholar 

  33. Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B, Multicenter Sitosterolemia Study Group. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004;109(8):71-966.

  34. Han J, Yang Y, Feng M, Wang G. [Analysis of phytosterol contents in Chinese plant food and primar estimation of its intake of people]. Wei Sheng Yan Jiu. 2007;36(3):301–5. Chinese.

    CAS  PubMed  Google Scholar 

  35. Bastida JM, Girós ML, Benito R, Janusz K, Hernández-Rivas JM, González-Porras JR. Sitosterolemia: Diagnosis, Metabolic and Hematological Abnormalities, Cardiovascular Disease and Management. Curr Med Chem. 2019;26(37):6766–75.

    CAS  Article  Google Scholar 

  36. Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, et al. Diagnosis and Management of Sitosterolemia 2021. J Atheroscler Thromb. 2021;28(8):791–801.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors thank the patient and their family for their invaluable contribution to this study.

Funding

This work was supported by the Medical Science and Technology Program of Guangdong Province, Grant/Award Number: 2017A02015111.

Author information

Authors and Affiliations

Authors

Contributions

ZZ performed the experiments, data collection, analysis and interpretation, article writing. XL provided overall guidance and participated in the design of the research strategy and questionnaire. XS participated in the design of the research strategy and manuscript preparation. TT critically revised the manuscript. WZ, XC, YL, AX, XM, CZ, LL conducted data collection. All authors approved the final version of this study.

Corresponding authors

Correspondence to Li Liu or Xiuzhen Li.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethics committee of the Guangzhou Women and Children’s Medical Center. Verbal consent was obtained from all participants. All respondents participated voluntarily and were informed that the survey data would be used for publication. The completion of the questionnaire means that the verbal consent is signed. The study does not involve individual privacy and it is not harmful to the individual. The procedures for verbal consent were approved by the ethics committee of the Guangzhou Women and Children’s Medical Center. Consent for publication Competing interests.

Consent for publication

All authors have read and approved the final submitted manuscript for publication.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhou, Z., Su, X., Cai, Y. et al. Features of chinese patients with sitosterolemia. Lipids Health Dis 21, 11 (2022). https://doi.org/10.1186/s12944-021-01619-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12944-021-01619-1

Keywords

  • Sitosterolemia
  • Xanthoma
  • Hypercholesterolemia
  • ABCG5
  • ABCG8